Zoetis Inc. $ZTS Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 14.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 119,919 shares of the company’s stock after selling 19,696 shares during the quarter. Pacer Advisors Inc.’s holdings in Zoetis were worth $17,547,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Zone Wealth Advisors LLC raised its stake in Zoetis by 6.5% during the third quarter. Blue Zone Wealth Advisors LLC now owns 34,746 shares of the company’s stock worth $5,084,000 after purchasing an additional 2,120 shares during the period. Cornercap Investment Counsel Inc. acquired a new stake in shares of Zoetis during the 3rd quarter worth approximately $1,598,000. Curbstone Financial Management Corp raised its position in shares of Zoetis by 1.6% during the 3rd quarter. Curbstone Financial Management Corp now owns 11,790 shares of the company’s stock valued at $1,725,000 after buying an additional 180 shares during the period. ZWJ Investment Counsel Inc. lifted its holdings in Zoetis by 33.0% in the third quarter. ZWJ Investment Counsel Inc. now owns 2,410 shares of the company’s stock valued at $353,000 after acquiring an additional 598 shares during the last quarter. Finally, Alhambra Investment Management LLC purchased a new position in Zoetis in the third quarter worth approximately $252,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.5%

Shares of ZTS opened at $126.16 on Friday. The company’s 50-day simple moving average is $127.05 and its 200-day simple moving average is $142.97. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.40. The stock has a market capitalization of $55.60 billion, a PE ratio of 21.24, a P/E/G ratio of 2.74 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a $0.53 dividend. The ex-dividend date is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s payout ratio is 35.69%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research analyst reports. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Barclays started coverage on shares of Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective on the stock. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research report on Thursday, December 18th. Finally, Bank of America lowered shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective on the stock. in a report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and an average target price of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.